Effectiveness of sildenafil and U-74389G in a rat model of colitis

Margonis, Georgios Antonios; Christoloukas, Nikolaos; Antoniou, Efstathios; Arkadopoulos, Nikolaos; Theodoropoulos, George; Agrogiannis, George; Pikoulis, Emmanouil; Patsouris, Efstratios; Zografos, Georgios; Papalois, Αpostolos

doi:10.1007/s13126-015-0217-2

Cited by 5 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of experiments have demonstrated that the MDA level in rats with TNBS colitis decreased after treatments using antioxidant and antiinflammatory agents [31,32]. In our study, the levels of the MDA in the colitis and vehicle control groups significantly increased compared to level of the RSV and Sham control groups (p < 0.01).…”

Section: Discussionsupporting

confidence: 48%

Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats

Yıldız¹,

Yildiz²,

Ulutaş³

et al. 2015

EMI

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic intestinal inflammatory disease in humans constituting a major health concern today whose prevalence has been increasing over the world. Production of reactive oxygen species (ROS) and disturbed capacity of antioxidant defense in IBD subjects have been reported. Antioxidants may play a significant role in IBD treatment. This study aimed at evaluating ameliorative effects of intraperitoneal resveratrol pretreatment on trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. Thirty five Wistar-Albino female rats were divided equally into five groups. Inflammation was induced by the intrarectal administration of TNBS under anesthesia. Intraperitoneal administration of resveratrol (RSV) at a concentration of 10mg/kg/day for 5 days before the induction of colitis significantly reduced microscopy score and malondialdehyde (MDA) levels and increased glutathione peroxidase (GSH Px) activity compared to TNBS and vehicle groups. Also an insignificant increase in catalase (CAT) activity was observed in the RSV treated group compared to TNBS and vehicle groups. In this paper, the most recent patent on the identification and treatment of IBD was indicated. In conclusion, antioxidant RSV proved to have a beneficial effect on TNBS colitis in rats. In light of these advantageous results, the RSV can be considered as adjuvant agent in IBD treatments.

show abstract

Section: Discussionsupporting

confidence: 48%

Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats

Yıldız¹,

Yildiz²,

Ulutaş³

et al. 2015

EMI

View full text Add to dashboard Cite

show abstract

“…In a rat model of colitis, Sildenafil prevented lipid peroxidation, cytokine production and neutrophil accumulation, Sildenafil reversed TNF-α and IL-1β in the colitis back to the control value (Iseri et al 2009). A recent study confirmed the anti-inflammatory effect of a PDE5I in a colitis model in rats (Margonis et al, 2015). Also, Sildenafil was found to be beneficial in AA-induced colitis in rats by preventing lipid peroxidation, cytokine release and maintaining oxidant anti-oxidant status (Ahmed et al, 2012).…”

Section: Discussionmentioning

confidence: 84%

Evaluation of the colo-protective effects of tadalafil in an experimental model of ulcerative colitis in rats

Labib¹,

Abdelzaher²,

Shaker³

et al. 2017

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

Ulcerative colitis is a serious premalignant condition with a confusing multifactorial pathogenesis. It should warrant all attention by researchers, for exploration of new prophylactic or therapeutic drugs targeting its pathophysiology. The current study was conducted to study the possible role of tadalafil and its potential actions in ulcerative colitis rat model, induced by acetic acid. Forty eight male Wistar albino rats were classified into 6 groups: control group, acetic acid (AA)-ulcerated group, AA-ulcerated + tadalafil (1 mg/kg/day), AA-ulcerated + tadalafil (5 mg/kg/day), AA-ulcerated + tadalafil (10 mg/kg/day) and AA-ulcerated + sulfasalazine 100 mg/kg/day groups. Tissue malondialdehyde (MDA), superoxide dismutase (SOD) and myeloperoxidase (MPO) were determined. Also, caspase-3 gene expression was measured as an indicator of apoptosis. Histopathological examination of the colonic tissue was also done. In addition, serum levels of interleukin (IL)-1β and tumour necrosis factor (TNF)-α were measured. In AA-ulcerated group, there was significant elevation in tissue MDA levels and MPO activity with upregulation of caspase 3 gene expression. Meanwhile, AA caused decreases in the SOD activities. Also, AA induced elevation in the serum IL-1β and TNF-α levels. Pretreatment with tadalafil in doses of 1, 5 and 10 mg/kg/days guarded against changes in these parameters. Its effects were dose-dependent. According to the results, pretreatment with tadalafil in doses of 1, 5 and 10 mg/kg/day exerted dosedependent beneficial effects against AA-induced damage of the colon, possibly by exerting antiinflammatory and antioxidant effects. Also, reduction of apoptosis proved to be one of the contributing protective mechanisms of actions.

show abstract

“…By contrast, treatment with a C5a aptamer increased the production of IL-7, IL-10, KC, IL-21, MIP-1α, MIP-1γ and TCA-3 in mice with TNBS-induced colitis. Colitis is characterized by an imbalance in pro-inflammatory and anti-inflammatory mediators, which may result in an exaggerated pro-inflammatory response, anti-inflammatory response syndrome, immunosuppression, apoptosis, organ dysfunction or clinical manifestations such as weight loss (26). The effect of C5a aptamer treatment in a mouse model of colitis was examined in the present study.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of C5a aptamers in a TNBS‑induced colitis mouse model

Wang

Chen

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. The complement-activated product, complement component 5a (C5a), is a potent inflammatory peptide with a broad spectrum of functions. In vivo and in vitro studies have demonstrated that C5a serves an important role in inflammation; however, the role of C5a in the pathogenesis of inflammatory bowel disease (IBD) is not known. The purpose of the current study was to investigate the role of C5a in IBD using an experimental mouse model of colitis. Colitis was induced in mice using 2,4,6-trinitrobenzene sulfonic acid (TNBS), and C5a aptamers were subsequently administered via intraperitoneal injection. Clinical symptoms of the disease, histopathological analysis of the colon and the level of inflammatory components were examined. The symptoms of colitis, including changes in behavior, weight loss, colon damage and an increase in inflammatory cytokines, were attenuated following the treatment of mice with TNBS-induced colitis with C5a aptamers. The aptamer-treated mice exhibited a marked attenuation of colitis when compared with untreated mice, as demonstrated by the phenotypic observations, histological examinations and inflammatory cytokine levels. Colitis is characterized by an imbalance between pro-inflammatory and anti-inflammatory mediators. The results of the current study suggest that C5a may serve a critical role in inflammation in IBD. IntroductionCrohn disease (CD) and ulcerative colitis (UC) are chronic relapsing gastrointestinal disorders, two main components of inflammatory bowel disease (IBD) (1). To date, the etiology of IBD is unknown; however, various inflammatory reactions constantly stimulate the mucosal and systemic immune systems and are involved in the inflammatory cascade (2). Approximately 25% of IBD cases occur before the age of 20 years, and 4% occur in persons younger than 5 years of age (3). In the treatment of IBD, a variety of pharmacological agents that target the inflammatory process are effective in controlling disease in patients and in sustaining symptomatic remission for prolonged periods, including tumor necrosis factor blockers, probiotics and corticosteroids (4).The complement system is widely considered to function to protect the host against invading microorganisms (5). However, previous studies investigating complement system activation have demonstrated that it may serve an injurious role in the pathogenesis of a number of inflammatory and immunological diseases (6,7). Complement activation products include complement component (C) 3a, C4a, C5a and C5b-9 and the membrane attack complex. C5a is an anaphylatoxin that exhibits chemotactic activities and promotes oxidative bursts, phagocytosis and the release of granule enzymes from neutrophils, monocytes and macrophages (7).A study involving C5a knockout mice has demonstrated that C5a serves a critical role in inflammatory diseases (8). Several inflammatory diseases have been attributed to the ability of C5a to bind with high-affinity C5a receptors (9,10), including the C5a anaphylatoxin chemotactic receptor and C5L2,...

show abstract

Effectiveness of sildenafil and U-74389G in a rat model of colitis

Cited by 5 publications

References 26 publications

Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats

Resveratrol Pretreatment Ameliorates TNBS Colitis in Rats

Evaluation of the colo-protective effects of tadalafil in an experimental model of ulcerative colitis in rats

Effectiveness of C5a aptamers in a TNBS‑induced colitis mouse model

Contact Info

Product

Resources

About